Insys Therapeutics to Present at the 2013 Wells Fargo Securities Healthcare Conference
PHOENIX, AZ -- (Marketwired) -- 06/11/13 -- Insys Therapeutics, Inc. (INSY), a specialty pharmaceutical company that develops and commercializes innovative supportive care products, today announced that it will participate in the 2013 Wells Fargo Securities Healthcare Conference in Boston, taking place on June 18-19, 2013.
President and Chief Executive Officer, Michael L. Babich, will participate in a presentation on Tuesday, June 18, 2013 at 1:10 p.m. ET. The presentation will be webcast live and available for replay at the Insys website www.insysrx.com.
About Insys Therapeutics, Inc.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company that develops and commercializes innovative supportive care products, with a focus on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has two marketed products including Subsys, a proprietary sublingual fentanyl spray for breakthrough pain in opioid-tolerant cancer patients. Insys markets Subsys through its incentive-based, cost-efficient commercial sales force. The company's lead product candidate is Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol, which would be its second branded supportive care product, if approved.
Company Contact: Darryl S. Baker Chief Financial Officer Insys Therapeutics, Inc. (602) 910-2617 Investor Contact: John Woolford Managing Director Westwicke Partners, LLC (443) 213-0506
Source: Insys Therapeutics